Edition:
United Kingdom

Foamix Pharmaceuticals Ltd (FOMX.OQ)

FOMX.OQ on NASDAQ Stock Exchange Global Market

5.69USD
16 Jul 2018
Change (% chg)

$-0.11 (-1.90%)
Prev Close
$5.80
Open
$5.82
Day's High
$5.86
Day's Low
$5.67
Volume
16,012
Avg. Vol
27,558
52-wk High
$7.43
52-wk Low
$4.35

Chart for

About

Foamix Pharmaceuticals Ltd. is a clinical-stage pharmaceutical company. The Company is engaged in the development and commercialization of foam-based formulations, using its technology, which includes its foam platforms. It is focused on developing and commercializing its minocycline foam for the treatment of acne, rosacea and... (more)

Overall

Beta: 1.96
Market Cap(Mil.): $234.92
Shares Outstanding(Mil.): 40.50
Dividend: --
Yield (%): --

Financials

  FOMX.OQ Industry Sector
P/E (TTM): -- 214.97 33.20
EPS (TTM): -2.06 -- --
ROI: -95.06 -3.79 13.23
ROE: -96.10 -5.32 15.28

BRIEF-Foamix Reports Fiscal Year 2017 Financial Results And Provides Corporate Update

* FOAMIX REPORTS FISCAL YEAR 2017 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

28 Feb 2018

BRIEF-Tamarkin Medical Reports 7.3 Percent Passive Stake In Foamix Pharmaceuticals

* TAMARKIN MEDICAL INNOVATIONS LTD REPORTS 7.3 PERCENT PASSIVE STAKE IN FOAMIX PHARMACEUTICALS AS OF DECEMBER 31, 2017 - SEC FILING Source text: (http://bit.ly/2so9g8s) Further company coverage:

13 Feb 2018

Earnings vs. Estimates